{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:53:05Z","timestamp":1776664385772,"version":"3.51.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    2-oxoglutarate-and iron-dependent oxygenase domain-containing protein 1(OGFOD1) is a prolyl hydroxylase that plays a pivotal role in regulating protein synthesis accuracy and efficiency. OGFOD1 is implicated in the pathogenesis of various cancers, including lung cancer, breast cancer and colonic cancer. A recent study highlights that under chemotherapy pressure, the upregulation of OGFOD1 promotes global protein synthesis via its catalytic activity, which is a key mechanism for AML chemoresistance. Deleting of OGFOD1 specifically compromises AML translation adaptability, thereby eradicating post-chemotherapy resistant cells and extending survival\n                    <jats:italic>in vivo<\/jats:italic>\n                    , while sparing normal hematopoiesis. Consequently, targeting OGFOD1 with identified inhibitors presents a promising therapeutic strategy to disrupt the translational adaptability of AML cells, potentially overcoming chemoresistance and improving patient outcomes. More importantly, there is an urgent need to develop highly selective OGFOD1-targeted agents with minimal toxicity.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1809489","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:24:02Z","timestamp":1776662642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["OGFOD1: a critical mediator of chemoresistance in acute myeloid leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Tingting","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyi","family":"Li","sequence":"additional","affiliation":[{"name":"Respiratory Intensive Care Unit, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liquan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Nursing, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[{"name":"Respiratory Intensive Care Unit, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunli","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.phytochem.2015.06.028","article-title":"The broad spectrum 2-oxoglutarate oxygenase inhibitor n-oxalylglycine is present in rhubarb and spinach leaves","volume":"117","author":"Al-Qahtani","year":"2015","journal-title":"Phytochemistry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (fg-4592) to treat anemia in nondialysis-dependent chronic kidney disease (Ndd-ckd) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1089\/hum.2024.113","article-title":"Advances in microrna therapeutics: from preclinical to clinical studies","volume":"35","author":"Brillante","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"115917","DOI":"10.1016\/j.celrep.2025.115917","article-title":"Identifying the target, mechanism, and agonist of alpha-ketoglutaric acid in delaying mesenchymal stem cell senescence","volume":"44","author":"Cui","year":"2025","journal-title":"Cell Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s42003-022-03805-y","article-title":"Mog analogues to explore the mct2 pharmacophore, alpha-ketoglutarate biology and cellular effects of n-oxalylglycine","volume":"5","author":"Fets","year":"2022","journal-title":"Commun. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/1873-3468.14547","article-title":"The prolyl hydroxylase ogfod1 promotes cancer cell proliferation by regulating the expression of cell cycle regulators","volume":"597","author":"Fujisaki","year":"2023","journal-title":"FEBS Lett."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/cvr\/cvab323","article-title":"Ogfod1 deletion increases cardiac beta-alanine levels and protects mice against ischaemia-reperfusion injury","volume":"118","author":"Harris","year":"2022","journal-title":"Cardiovasc Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.str.2015.01.014","article-title":"Structure of the ribosomal oxygenase ogfod1 provides insights into the regio- and stereoselectivity of prolyl hydroxylases","volume":"23","author":"Horita","year":"2015","journal-title":"Structure"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.1314485111","article-title":"Sudestada1, a drosophila ribosomal prolyl-hydroxylase required for mrna translation, cell homeostasis, and organ growth","volume":"111","author":"Katz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19528","DOI":"10.18632\/oncotarget.3683","article-title":"Ogfod1 is required for breast cancer cell proliferation and is associated with poor prognosis in breast cancer","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1101\/gad.313007.118","article-title":"The aryl hydrocarbon receptor regulates nucleolar activity and protein synthesis in myc-expressing cells","volume":"32","author":"Lafita-Navarro","year":"2018","journal-title":"Genes Dev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3390\/cancers13143418","article-title":"Phosphorylation of ogfod1 by cell cycle-dependent kinase 7\/9 enhances the transcriptional activity of rna polymerase ii in breast cancer cells","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"106749","DOI":"10.1016\/j.leukres.2021.106749","article-title":"A phase ii study of sequential decitabine and rapamycin in acute myelogenous leukemia","volume":"112","author":"Liesveld","year":"2022","journal-title":"Leuk. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/0008-5472.CAN-09-3143","article-title":"Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated b-cell antigens","volume":"70","author":"Marina","year":"2010","journal-title":"Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.cmet.2025.08.008","article-title":"Ogfod1 enables aml chemo- and nutrient stress resistance by regulating protein synthesis","volume":"37","author":"Mayerhofer","year":"2025","journal-title":"Cell Metab."},{"key":"B16","volume-title":"Clinical review report: Nitisinone (orfadin): (sobi Canada inc.): indication: for the treatment of patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine","year":"2018"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1073\/pnas.1314482111","article-title":"Ogfod1 catalyzes prolyl hydroxylation of rps23 and is involved in translation control and stress granule formation","volume":"111","author":"Singleton","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/chem.201804790","article-title":"Selective inhibitors of a human prolyl hydroxylase (ogfod1) involved in ribosomal decoding","volume":"25","author":"Thinnes","year":"2019","journal-title":"Chemistry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1128\/MCB.01350-09","article-title":"Ogfod1, a novel modulator of eukaryotic translation initiation factor 2alpha phosphorylation and the cellular response to stress","volume":"30","author":"Wehner","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2183947","DOI":"10.1080\/13685538.2023.2183947","article-title":"Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer","volume":"26","author":"Wu","year":"2023","journal-title":"Aging Male"},{"key":"B21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12967-024-04993-3","article-title":"Inhibition of ogfod1 by fg4592 confers neuroprotection by activating unfolded protein response and autophagy after ischemic stroke","volume":"22","author":"Xie","year":"2024","journal-title":"J. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00438-020-01649-x","article-title":"Ogfod1 negatively regulated by mir-1224-5p promotes proliferation in human papillomavirus-infected laryngeal papillomas","volume":"295","author":"Yin","year":"2020","journal-title":"Mol. Genet. Genomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1009331","DOI":"10.1080\/21690731.2015.1009331","article-title":"Modifying the maker: oxygenases target ribosome biology","volume":"3","author":"Zhuang","year":"2015","journal-title":"Transl. (Austin)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1809489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:24:03Z","timestamp":1776662643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1809489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":23,"alternative-id":["10.3389\/fphar.2026.1809489"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1809489","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1809489"}}